Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study

[1]  C. Crainiceanu,et al.  Outer retinal changes following acute optic neuritis , 2016, Multiple sclerosis.

[2]  H. Ishikawa,et al.  Acute optic neuritis , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[3]  M. Fredrikson,et al.  Benign Multiple Sclerosis is Associated with Reduced Thinning of the Retinal Nerve Fiber and Ganglion Cell Layers in Non-Optic-Neuritis Eyes , 2015, Journal of clinical neurology.

[4]  Snehashis Roy,et al.  Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four‐year study , 2015, Annals of neurology.

[5]  I. Zubizarreta,et al.  Dynamics of retinal injury after acute optic neuritis , 2015, Annals of neurology.

[6]  Brandon D Gallas,et al.  Comparing two correlated C indices with right‐censored survival outcome: a one‐shot nonparametric approach , 2015, Statistics in medicine.

[7]  Marram P. Olson,et al.  Precision medicine in chronic disease management: The multiple sclerosis BioScreen , 2014, Annals of neurology.

[8]  Mike P. Wattjes,et al.  The investigation of acute optic neuritis: a review and proposed protocol , 2014, Nature Reviews Neurology.

[9]  Jeffrey A. Cohen,et al.  Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.

[10]  C. Cadarso-Suárez,et al.  Retinal Nerve Fiber Layer Thickness, Brain Atrophy, and Disability in Multiple Sclerosis Patients , 2014, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[11]  H. Wiendl,et al.  Clinical Relevance of Brain Volume Measures in Multiple Sclerosis , 2014, CNS Drugs.

[12]  Sara Llufriu,et al.  Trans‐synaptic axonal degeneration in the visual pathway in multiple sclerosis , 2014, Annals of neurology.

[13]  S. A. Meyer,et al.  Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning , 2013, Neurology.

[14]  C. Crainiceanu,et al.  Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study , 2012, The Lancet Neurology.

[15]  A. Ambrosi,et al.  Retinal nerve fiber layer thickness reproducibility using seven different OCT instruments. , 2012, Investigative Ophthalmology and Visual Science.

[16]  F. Paul,et al.  Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography , 2012, Multiple sclerosis international.

[17]  P. Albrecht,et al.  Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography , 2012, Multiple sclerosis.

[18]  Amy Conger,et al.  The Impact of Utilizing Different Optical Coherence Tomography Devices for Clinical Purposes and in Multiple Sclerosis Trials , 2011, PloS one.

[19]  F. Paul,et al.  Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. , 2011, Brain : a journal of neurology.

[20]  U. Schmidt-Erfurth,et al.  High Resolution Spectral Domain Optical Coherence Tomography (SD-OCT) in Multiple Sclerosis: The First Follow Up Study over Two Years , 2011, PloS one.

[21]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[22]  P. Villoslada.  Biomarkers for multiple sclerosis. , 2010, Drug news & perspectives.

[23]  Axel Petzold,et al.  Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis , 2010, The Lancet Neurology.

[24]  I. Allen,et al.  Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. , 2010, Brain : a journal of neurology.

[25]  C. Pfueller,et al.  Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study , 2010, Multiple sclerosis.

[26]  C. Polman,et al.  Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis , 2010, Multiple sclerosis.

[27]  C. Polman,et al.  Assessing disability progression with the Multiple Sclerosis Functional Composite , 2009, Multiple sclerosis.

[28]  S. Hauser,et al.  The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration , 2006, Neuron.

[29]  Fiona Costello,et al.  Quantifying axonal loss after optic neuritis with optical coherence tomography. , 2006, Annals of neurology.

[30]  Douglas G Altman,et al.  Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls , 2002, The Lancet.

[31]  Christian Confavreux,et al.  Recommendations from the national multiple sclerosis society clinical outcomes assessment task force , 1997, Annals of neurology.

[32]  J. Concato,et al.  Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. , 1995, Journal of clinical epidemiology.

[33]  P Peduzzi,et al.  Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. , 1995, Journal of clinical epidemiology.

[34]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[35]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.